CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc.

Share Article

CanDiag has changed its name to OncoTab, Inc.

OncoTab

We’ve extended our platform’s applications beyond breast cancer diagnostics to include imaging and therapies, and our new name is a reflection of that evolution.

CanDiag, Inc., a University of North Carolina at Charlotte (UNC Charlotte) spin-out company has changed its name to OncoTab, Inc.

“The new name is a more accurate representation of where we are today,” said CEO and Chief Science Officer, Dr. Pinku Mukherjee, PhD. “We’ve extended our platform’s applications beyond breast cancer diagnostics to include imaging and therapies, and our new name is a reflection of that evolution.”

Founded in 2011 by Dr. Mukherjee, an Irwin Belk Endowed Professor for Cancer Research at UNC Charlotte, to pursue diagnostic applications for breast cancer, OncoTab has now executed a worldwide exclusive license from UNC Charlotte to additional applications of its technology platform that include tumor imaging and therapies. OncoTab has raised close to $1.8 million to date and is conducting proof of concept studies that have demonstrated the capability of its platform to specifically target tumors.

This press release is not an offer to sell or the solicitation of an offer to buy shares or any other security in any jurisdiction.

About OncoTab, Inc.
OncoTab (http://www.oncotab.com) is a University of North Carolina at Charlotte (UNC Charlotte) spin-out that has licensed a patent-protected technology from the university with applications spanning the life cycle of cancer patients, from detecting and locating cancer to treatment and monitoring for recurrence. The company is gearing up for a pivotal clinical study of its blood test and is pursuing additional diagnostic, imaging, and therapeutic product development and commercialization in the cancer space.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Liz Roop
Visit website